MiddleBrook Pharmaceuticals, Inc., formerly Advancis Pharmaceutical Corporation is a pharmaceutical company focused on developing and commercializing anti-infective drug products that fulfill unmet medical needs. The Company developed a delivery technology called PULSYS, which enables the pulsatile delivery, or delivery in rapid bursts, of certain drugs. It is approved for the treatment of pharyngitis/tonsillitis secondary to Streptococcus pyogenes, commonly known as strep throat, for adults and pediatric patients age 12 and older. The Company operates in one business segment: prescription pharmaceuticals. The Company markets KEFLEX (Cephalexin, USP) capsules, to wholesalers in capsule formulations.